Tvardi Therapeutics, Inc.
TVRDNext catalyst
TTI-101
Hepatocellular Carcinoma
Get an email about TVRD's next catalysts
Track Tvardi Therapeutics (TVRD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
TVRD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.51 | FQ end Sep/2026 | Call: tbd
TTI-101 Phase 2 Est. Readout
Estimated primary completion for TTI-101 trial (NCT05440708) in Hepatocellular Carcinoma. Topline data typically follows completion by weeks to months.
SourceHow TVRD's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TTI-101 | Phase 2 | Hepatocellular Carcinoma | - | - |
Frequently asked questions
What is in Tvardi Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Tvardi Therapeutics, Inc.'s (TVRD) pipeline across Phase 2. Its lead program is TTI-101 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tvardi Therapeutics, Inc.'s next FDA catalyst?→
Tvardi Therapeutics, Inc.'s (TVRD) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TVRD biotech catalysts?→
Add TVRD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tvardi Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.